Aurobindo, Hetero, and Vivimed Class Action Settlements

All class action lawsuits and settlements involving Aurobindo, Hetero, and Vivimed.

Aurobindo Pharma, Hetero Labs, and Vivimed Life Sciences have faced significant legal action over contaminated blood pressure medications, resulting in a major class action settlement for affected consumers. These pharmaceutical companies were involved in manufacturing and distributing valsartan, losartan, and irbesartan medications that contained potentially cancer-causing impurities, leading to widespread recalls and patient safety concerns. The companies have agreed to a substantial $15.2 million settlement to compensate individuals who purchased or consumed these contaminated medications between specific time periods. Currently, there is one active settlement available for claims, with no expired settlements at this time. The settlement covers patients who took the affected blood pressure medications and may have been exposed to NDMA, NDEA, or other nitrosamine impurities that were discovered in various batches of these drugs. Eligible claimants may include individuals who purchased these medications directly or through insurance, as well as those who experienced medical complications potentially related to the contaminated drugs. The legal action stems from manufacturing defects and quality control failures at facilities operated by these companies, which supplied generic versions of these widely-prescribed cardiovascular medications to millions of patients across the United States. Class Action Buddy streamlines the claims process by providing step-by-step guidance and automated form completion to help you secure your settlement compensation quickly.

How do I know if I qualify for the Aurobindo, Hetero, and Vivimed class action settlement?

You may qualify for the $15.2 million settlement if you purchased Valsartan, Losartan, or Irbesartan medications manufactured by Aurobindo, Hetero, or Vivimed that contained NDMA or other nitrosamine impurities. The settlement covers consumers who bought these blood pressure medications between specific dates when the contaminated drugs were distributed. You'll need proof of purchase or prescription records to submit a claim.

Has Aurobindo, Hetero, and Vivimed settled any class action lawsuits?

Yes, Aurobindo, Hetero, and Vivimed reached a $15.2 million class action settlement related to contaminated blood pressure medications. The settlement resolves claims that these pharmaceutical companies sold Valsartan, Losartan, and Irbesartan drugs containing cancer-causing NDMA and other nitrosamine impurities.

What is the Valsartan, Losartan and Irbesartan settlement amount for Aurobindo, Hetero, and Vivimed?

The total settlement amount is $15.2 million for the Valsartan, Losartan, and Irbesartan class action against Aurobindo, Hetero, and Vivimed. This settlement fund will be distributed among eligible class members who purchased the contaminated blood pressure medications. Individual payouts will depend on the number of valid claims submitted and the specific medications purchased.

What blood pressure medications are covered in the Aurobindo, Hetero, and Vivimed settlement?

The settlement covers Valsartan, Losartan, and Irbesartan blood pressure medications manufactured by Aurobindo, Hetero, and Vivimed. These ARB (Angiotensin Receptor Blocker) drugs were found to contain NDMA and other nitrosamine impurities that are classified as probable human carcinogens. The contaminated medications were recalled after the FDA discovered the cancer-causing substances.

Learn more about Aurobindo, Hetero, and Vivimed

Aurobindo, Hetero, and Vivimed Settlements by State

Find Aurobindo, Hetero, and Vivimed class action settlements available in your state.

Related Resources